fatnews.com Fatnews Bitchute Channel Link Home page  >  Article | Previous article | Next article



  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • More deaths in Covid-19 patients given remdesivir than placebo, 15% vs 13%

    Posted by .(JavaScript must be enabled to view this email address)
    Wednesday, May 13, 2020 4:14 pm Email this article

    On April 29, 2020 Dr. Anthony Fauci, one of the leads on the coronavirus Task Force for the White House on Covid-19, said that there is “clearcut evidence” that Remdesivir works for Covid-19, and that it is now the new “standard of care.”

    Here are the results of another study that questions whether this is true or not.

    A randomized, placebo-controlled Chinese trial found that 15% of those with Covid-19 given remdesivir died versus 13% of those given a placebo.

    In other words, people given remdesivir were more likely to die than those given a placebo.


    The press release for the Chinese trial of the drug stated:

    “Participants in our trial were less ill, and treated earlier in their disease course, compared with a recent observational study of patients with COVID-19, who received remdesivir on compassionate grounds [4]. Yet, remdesivir did not provide greater benefits in our study population as expected”, says co-author Professor Ronghui Du from Wuhan Lung Hospital, China.

    Conflicts of Interest on Panel Coming Up With Guidelines for Covid-19

    Eight (8) people have been paid by Gilead Sciences, the makers of Remdesivir

    It is also worth noting that eight (8) people on the panel coming up with treatment guidelines for Covid-19 have been paid by Gilead Sciences, the makers of Remdesivir.


    Articles on the same subject can be found here:


    Please feel free to share your comments about this article.




    Please enter the word you see in the image below:

    Remember my personal information

    Notify me of follow-up comments?

    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.